Royalty Pharma (RPRX) Intangibles (2019 - 2021)

Royalty Pharma (RPRX) has 3 years of Intangibles data on file, last reported at $5.7 million in Q4 2021.

• For the quarter ending Q4 2021, Intangibles fell 80.22% year-over-year to $5.7 million; the trailing twelve-month figure through Dec 2021 stood at $5.7 million (down 80.22% YoY), and the FY2021 full-year result was $5.7 million, down 80.22% from the prior year.
• Intangibles retreated to $5.7 million in Q4 2021, from $11.5 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $51.7 million in Q4 2019 to a low of $5.7 million in Q4 2021.
• A 3-year average of $26.6 million and a median of $25.8 million in 2020 frame the typical range for Intangibles.
• Across the five-year window, Intangibles tumbled 44.58% in 2020 and sank 80.22% in 2021, its largest moves.
• Tracing RPRX's Intangibles over 3 years: stood at $51.7 million in 2019, then plunged by 44.58% to $28.7 million in 2020, then slumped by 80.22% to $5.7 million in 2021.
• Business Quant data shows RPRX's Intangibles at $5.7 million in Q4 2021, $11.5 million in Q3 2021, and $17.3 million in Q2 2021.